SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-004169 to Genfit S.A. (GNFT) (CIK 0001757064) (GNFTY)

Genfit S.A. (GNFT) (CIK 0001757064)
Date: April 25, 2023 · CIK: 0001757064 · Accession: 0000000000-23-004169

AI Filing Summary & Sentiment

File numbers found in text: 333-271312

Date
April 25, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Genfit S.A. (GNFT) (CIK 0001757064)

Letter

United States securities and exchange commission logo April 25, 2023 Pascal Prigent Chief Executive Officer Genfit S.A. 19 West 44th Street, Suite 200 New York, New York 10036 Re:Genfit S.A. Registration Statement on Form F-3 Filed April 18, 2023 File No. 333-271312 Dear Pascal Prigent: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian Leaf, Esq.

Show Raw Text
United States securities and exchange commission logo
April 25, 2023
Pascal Prigent
Chief Executive Officer
Genfit S.A.
19 West 44th Street, Suite 200
New York, New York 10036
Re:Genfit S.A.
Registration Statement on Form F-3
Filed April 18, 2023
File No. 333-271312
Dear Pascal Prigent:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Brian Leaf, Esq.